2024
Immune landscape of oncohistone-mutant gliomas reveals diverse myeloid populations and tumor-promoting function
Andrade A, Annett A, Karimi E, Topouza D, Rezanejad M, Liu Y, McNicholas M, Gonzalez Santiago E, Llivichuzhca-Loja D, Gehlhaar A, Jessa S, De Cola A, Chandarana B, Russo C, Faury D, Danieau G, Puligandla E, Wei Y, Zeinieh M, Wu Q, Hebert S, Juretic N, Nakada E, Krug B, Larouche V, Weil A, Dudley R, Karamchandani J, Agnihotri S, Quail D, Ellezam B, Konnikova L, Walsh L, Pathania M, Kleinman C, Jabado N. Immune landscape of oncohistone-mutant gliomas reveals diverse myeloid populations and tumor-promoting function. Nature Communications 2024, 15: 7769. PMID: 39237515, PMCID: PMC11377583, DOI: 10.1038/s41467-024-52096-w.Peer-Reviewed Original ResearchConceptsMyeloid populationsTumor microenvironmentExpression of immune checkpoint markersImmune checkpoint pathwaysImmune checkpoint markersSyngeneic mouse modelTumor-promoting functionsCheckpoint markersMyeloid infiltrationImmune landscapeImmune infiltrationImmune lineagesMyeloid cellsLymphoid cellsTumor cellsMouse modelTumor formationBenefit of patientsTherapeutic benefitBrain tumorsGliomaTumorDysregulated epigenomeDual inhibitionInfiltrationWaiting list mortality and 5-year transplant survival benefit of patients with MASLD: An Italian liver transplant registry study
Vitale A, Trapani S, Russo F, Miele L, Baroni G, Marchesini G, Burra P, Ottoveggio M, Romagnoli R, Martini S, De Simone P, Carrai P, Cescon M, Morelli M, De Carlis L, Belli L, Gruttadauria S, Volpes R, Colledan M, Fagiuoli S, Di Benedetto F, De Maria N, Rossi G, Caccamo L, Donato F, Vennarecci G, Di Costanzo G, Vivarelli M, Carraro A, Sacerdoti D, Ettorre G, Giannelli V, Agnes S, Gasbarrini A, Rossi M, Corradini S, Mazzaferro V, Bhoori S, Manzia T, Lenci I, Zamboni F, Mameli L, Baccarani U, Toniutto P, Lupo L, Tandoi F, Rendina M, Andorno E, Giannini E, Spada M, Billato I, Marchini A, Romano P, Brancaccio G, D’Amico F, Ricci A, Cardillo M, Cillo U, del Fegato . A, . S, Trapianti C. Waiting list mortality and 5-year transplant survival benefit of patients with MASLD: An Italian liver transplant registry study. JHEP Reports 2024, 6: 101147. PMID: 39282226, PMCID: PMC11399673, DOI: 10.1016/j.jhepr.2024.101147.Peer-Reviewed Original ResearchSurvival benefit of patientsTransplant survival benefitHepatocellular carcinomaLiver transplantationLiver diseaseIncreased waitlist mortalityPatient survivalBenefit of patientsSteatotic liver diseaseEnd-stage chronic liver diseaseAbstractText Label="Background &Waiting listImprove patient survivalWaitlist mortalityLiver transplant indicationsChronic liver diseaseAlcoholic liver diseaseRisk of deathWaiting list mortalityAbstractText Label="ImpactPrognostic featuresTransplant eligibility criteriaSurvival benefitTransplant indicationAdult patients
2020
Geographical affiliation with top 10 NIH-funded academic medical centers and differences between mortality from cardiovascular disease and cancer
Angraal S, Caraballo C, Kahn P, Bhatnagar A, Singh B, Wilson FP, Fiuzat M, O'Connor CM, Allen LA, Desai NR, Mamtani R, Ahmad T. Geographical affiliation with top 10 NIH-funded academic medical centers and differences between mortality from cardiovascular disease and cancer. American Heart Journal 2020, 230: 54-58. PMID: 32950462, PMCID: PMC7734611, DOI: 10.1016/j.ahj.2020.08.014.Peer-Reviewed Original ResearchConceptsCardiovascular mortality ratesMortality rateCardiovascular mortalityCancer mortalityCardiovascular diseaseMedical CenterIndex groupAnnual cardiovascular mortality rateCardiovascular mortality trendsCancer mortality ratesAcademic medical centerBenefit of patientsMortality trendsSociodemographic characteristicsMortalityIncremental benefitComparison groupNIH fundingImplementation scienceNIHHigh rateDiseaseRapid translationAverage declineResearch priorities
2019
Metastatic Cancers to Bone: An Overview and Cancer-Induced Bone Loss.
Ibe IK, Sahlstrom A, White A, Henderson SE, Lee FY. Metastatic Cancers to Bone: An Overview and Cancer-Induced Bone Loss. Instructional Course Lectures 2019, 68: 547-556. PMID: 32032068.Peer-Reviewed Original ResearchConceptsCancer-induced bone lossBone lossBone metastasesMetastatic bone diseaseCancer cellsDegree of osteolysisNormal bone homeostasisBenefit of patientsOsteolytic metastasesSkeletal metastasesPatient functionSurgical stabilizationWorse prognosisLocal bone massBone massMetastatic cancerBone diseaseRadiation therapyTherapeutic modalitiesBone homeostasisImmune systemOverall outcomeMetastasisBone remodelingPatients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply